63720-49-0

Upstream product

• 61147-43-1 4-cyano-2-benzyloxypyridine 
• 6921-34-2 benzylmagnesium chloride 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 873-62-1 m-cyanophenol 
• 100-44-7 benzyl chloride 

Downstream Products

• 1027497-98-8 6-(3-Benzyloxy-phenyl)-6-oxo-5-phenyl-hexanoic acid methyl ester 
• 170279-88-6 methyl (RS)-4-(3-benzyloxyphenyl)-4-oxo-3-phenylbutanoate 
• 180209-46-5 2-benzyl-2-(3-benzyloxy-phenyl)-[1,3]dioxolane 
• 170279-17-1 (RS)-5-(3-benzyloxyphenyl)-5-oxo-4-phenylpentanoic acid 
• 180209-50-1 2-(2-benzyl-[1,3]dioxolan-2-yl)-6-benzyloxy-benzoic acid methyl ester 
• 180209-54-5 2-(2-benzyl-[1,3]dioxolan-2-yl)-6-hydroxy-benzoic acid methyl ester 
• 180209-57-8 Methyl 6-phenylacetylsalicylate 
• 170279-66-0 methyl (RS)-5-(3-benzyloxyphenyl)-5-oxo-4-phenylpentanoate 

Relevant academic research and scientific papers

Substituted phenyl compounds

Compounds of formula (I) are described wherein R1is hydrogen, -(lower alkyl)q(CO2R6or OH), —CN, —C(R7)═NOR8, NO2, —O(lower alkyl)R9, —C≡C—R10, —CR11═C(R12)(R13), —C(═O)CH2C(═O)CO2H, —CO(R14), alkylthio, alkylsulphinyl, alkylsulphonyl, carbamoyl, thiocarbamoyl, substituted carbamoyl, substituted thiocarbamoyl, sulphamoyl or an optionally substituted nitrogen-containing ring, m, n, o and p are independently zero or 1 and R2, R3, R4and R5are various groups; and physiologically acceptable salts, N-oxides and prodrugs thereof. The compounds have endothelin antagonist activity and are useful as pharmaceuticals.

Selective endothelin A receptor antagonists. 2. Discovery and structure-activity relationships of 5-ketopentanoic acid derivatives

The second in this series of papers describes the further progress made in the discovery of a potent and selective endothelin ET(A) receptor antagonist for the potential treatment of diseases in which endothelin has been shown to have a pathophysiological role including hypertension, ischaemic diseases and atherosclerosis. We describe herein the synthesis and structure-activity relationships of a novel series of 5-ketopentanoic acid derivatives exemplified by the lead compound 1 (IC50 0.72 μM, rat aortic ET(A)R). Optimisation of the in vitro binding of 1 led to the identification of a more potent compound (37) which exhibited an IC50 300-fold selectivity for the ET(A) receptor over the ET(B) receptor. This compound demonstrated functional antagonism of endothelin-induced vasoconstriction in vitro.

Studies of the new herbicide KIH-6127. Part II. Synthesis and herbicidal activity of 6-acyl pyrimidin-2-yl salicylates and analogues against barnyard grass

The method reported previously (Part I) was employed to prepare a variety of novel 6-acylsalicylates as key intermediates. 6-Acylpyrimidin-2- yl salicylates (2-acyl-6-[(4,6-disubstituted pyrimidin-2-yl)oxy]benzoate derivatives: Type 1), the closely relate